BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 37014547)

  • 1. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
    Gusarova VD; Smolov MA; Lyagoskin IV; Degterev MB; Rechetnik EV; Rodionov AV; Pantyushenko MS; Shukurov RR
    BioDrugs; 2023 May; 37(3):375-395. PubMed ID: 37014547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein.
    Lu JZ; Boado RJ; Hui EK; Zhou QH; Pardridge WM
    Biotechnol Bioeng; 2011 Aug; 108(8):1954-64. PubMed ID: 21351076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution of Idursulfase Formulated for Intrathecal Use (Idursulfase-IT) in Cynomolgus Monkeys after Intrathecal Lumbar Administration.
    Chung JK; Brown E; Crooker B; Palmieri KJ; McCauley TG
    PLoS One; 2016; 11(10):e0164765. PubMed ID: 27764180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration.
    Xie H; Chung JK; Mascelli MA; McCauley TG
    PLoS One; 2015; 10(4):e0122453. PubMed ID: 25836678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.
    Arguello A; Meisner R; Thomsen ER; Nguyen HN; Ravi R; Simms J; Lo I; Speckart J; Holtzman J; Gill TM; Chan D; Cheng Y; Chiu CL; Dugas JC; Fang M; Lopez IA; Solanoy H; Tsogtbaatar B; Zhu Y; Bhalla A; Henne KR; Henry AG; Delucchi A; Costanzo S; Harris JM; Diaz D; Scearce-Levie K; Sanchez PE
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.
    Lu JZ; Hui EK; Boado RJ; Pardridge WM
    Bioconjug Chem; 2010 Jan; 21(1):151-6. PubMed ID: 20000684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
    Sonoda H; Morimoto H; Yoden E; Koshimura Y; Kinoshita M; Golovina G; Takagi H; Yamamoto R; Minami K; Mizoguchi A; Tachibana K; Hirato T; Takahashi K
    Mol Ther; 2018 May; 26(5):1366-1374. PubMed ID: 29606503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II.
    Wood SR; Chaudrhy A; Ellison S; Searle R; Burgod C; Tehseen G; Forte G; O'Leary C; Gleitz H; Liao A; Cook J; Holley R; Bigger BW
    Hum Gene Ther; 2024 Apr; 35(7-8):232-242. PubMed ID: 37212263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.
    Boado RJ; Ka-Wai Hui E; Zhiqiang Lu J; Pardridge WM
    Biotechnol Bioeng; 2014 Nov; 111(11):2317-25. PubMed ID: 24889100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
    Okuyama T; Eto Y; Sakai N; Minami K; Yamamoto T; Sonoda H; Yamaoka M; Tachibana K; Hirato T; Sato Y
    Mol Ther; 2019 Feb; 27(2):456-464. PubMed ID: 30595526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO
    Yamamoto R; Kawashima S
    Nihon Yakurigaku Zasshi; 2022; 157(1):62-75. PubMed ID: 34980815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil.
    Giugliani R; Martins AM; So S; Yamamoto T; Yamaoka M; Ikeda T; Tanizawa K; Sonoda H; Schmidt M; Sato Y
    Mol Ther; 2021 Jul; 29(7):2378-2386. PubMed ID: 33781915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome.
    Chung YK; Sohn YB; Sohn JM; Lee J; Chang MS; Kwun Y; Kim CH; Lee JY; Yook YJ; Ko AR; Jin DK
    Glycoconj J; 2014 May; 31(4):309-15. PubMed ID: 24781369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey.
    Boado RJ; Hui EK; Lu JZ; Sumbria RK; Pardridge WM
    Bioconjug Chem; 2013 Oct; 24(10):1741-9. PubMed ID: 24059813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II.
    Hoshina H; Shimada Y; Higuchi T; Kobayashi H; Ida H; Ohashi T
    Mol Genet Metab; 2018 Feb; 123(2):118-122. PubMed ID: 29289480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of
    Smith MC; Belur LR; Karlen AD; Erlanson O; Podetz-Pedersen KM; McKenzie J; Detellis J; Gagnidze K; Parsons G; Robinson N; Labarre S; Shah S; Furcich J; Lund TC; Tsai HC; McIvor RS; Bonner M
    Hum Gene Ther; 2022 Dec; 33(23-24):1279-1292. PubMed ID: 36226412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles.
    Rigon L; Salvalaio M; Pederzoli F; Legnini E; Duskey JT; D'Avanzo F; De Filippis C; Ruozi B; Marin O; Vandelli MA; Ottonelli I; Scarpa M; Tosi G; Tomanin R
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.